DLDaphne Y. Lichtensztajn

Daphne Y. Lichtensztajn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daphne Y. Lichtensztajn has a total of 200 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluating Disparities in Pediatric Cancer Genomic Testing and Sequencing Results at the University of California, San Francisco Using the National Childhood Cancer Registry

    by Meera Sangaramoorthy, Anushka Walia, Michelle Turski, Annie Vu, Daphne Lichtensztajn, Colin Huang, Ana Golla, Scarlett L. Gomez, Lena E. Winestone

    PURPOSE: The increasing role of genomic testing in pediatric cancer care decisions may contribute to outcome disparities. We evaluated drivers of genomic testing in the National Childhood Cancer Registry (NCCR) at the University of California, San Francisco (UCSF). MATERIALS AND METHODS: Multilevel data linkages for 1,555 patients with cancer age ≤20 years diagnosed between 2012 and 2019 at the UCSF NCCR were leveraged for a subset of patients who were alive and diagnosed after 2015 following the availability of UCSF500 genomic testing, a panel-based, next-generation cancer tumor and normal sequencing assay. Risk ratios (RR) and 95% CI of testing were estimated using Poisson regression. The prevalence of pathogenic variants and variants of uncertain significance (VUS) was generated for tested patients. RESULTS: Of the 758 eligible patients, 262 (34.6%) were tested. In fully adjusted models, adoption of genomic testing increased over time (2019 v 2016: RR, 2.06 [95% CI, 1.49 to 2.86]), whereas older age (ages 15-19 v <5 years: RR, 0.69 [95% CI, 0.52 to 0.91]), female versus male sex (RR, 0.81 [95% CI, 0.66 to 0.98]), and living in a rural versus urban/suburban area (RR, 0.60 [95% CI, 0.38 to 0.96]) were independently associated with lower genomic testing. Compared with solid tumors, lymphomas were less likely (RR, 0.49 [95% CI, 0.24 to 0.98]) and CNS tumors were more likely (RR, 1.70 [95% CI, 1.37 to 2.12]) to be tested. Among the tested patients, the prevalence of pathogenic variants and VUS did not differ by race/ethnicity or neighborhood socioeconomic status. CONCLUSION: Our work highlights the need for more equitable genomic testing practices in pediatric cancer care to reduce clinical outcome disparities and demonstrates how the population-based integrated database generated for the UCSF NCCR serves as a valuable resource for advancing epidemiologic research for patients with pediatric cancer.

  • Open Access

    Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019

    by Kevin L'ESpérance, Katherine Lin, Daphne Lichtensztajn, Simon John Christoph Soerensen, Shuchi Gulati, Zhengyi Deng, John T. Leppert, David Y. Oh, Lori C. Sakoda, Samuel L. Washington, et al.


  • Open Access

    Supplementary Table S2 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population

    by Daphne Y. Lichtensztajn, Brenda M. Hofer, John T. Leppert, James D. Brooks, Benjamin I. Chung, Sumit A. Shah, Mindy C. DeRouen, Iona Cheng

    Supplementary Table S2 shows the associations of comorbidity with RCC subtype stratified by race and ethnicity and by sex

  • Open Access

    Supplementary Table S4 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population

    by Daphne Y. Lichtensztajn, Brenda M. Hofer, John T. Leppert, James D. Brooks, Benjamin I. Chung, Sumit A. Shah, Mindy C. DeRouen, Iona Cheng

    Supplementary Table S4 shows the results of sensitivity analyses using different comorbidity definitions

  • Open Access

    Supplementary Table S1 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population

    by Daphne Y. Lichtensztajn, Brenda M. Hofer, John T. Leppert, James D. Brooks, Benjamin I. Chung, Sumit A. Shah, Mindy C. DeRouen, Iona Cheng

    Supplementary Table S1 lists the ICD-9 and ICD-10 codes used to define comorbidities

  • Open Access

    Data from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population

    by Daphne Y. Lichtensztajn, Brenda M. Hofer, John T. Leppert, James D. Brooks, Benjamin I. Chung, Sumit A. Shah, Mindy C. DeRouen, Iona Cheng

    Background:Renal cell carcinoma (RCC) subtypes differ in molecular characteristics and prognosis. We investigated the associations of RCC subtype with patient demographics, comorbidity, and neighborhood socioeconomic status (nSES).Methods:Using linked California Cancer Registry and Office of Statewide Health Planning and Development data, we identified history of hypertension, diabetes, and kidney disease prior to RCC diagnosis in Asian/Pacific Islander, non-Latino Black, Latino, and non-Latino White adults diagnosed with their first pathologically confirmed RCC from 2005 through 2015. We used multinomial multivariable logistic regression to model the association of demographics, comorbidity, and nSES with clear-cell, papillary, and chromophobe RCC subtype.Results:Of the 40,016 RCC cases included, 62.6% were clear cell, 10.9% papillary, and 5.9% chromophobe. The distribution of subtypes differed strikingly by race and ethnicity, ranging from 40.4% clear cell and 30.4% papillary in non-Latino Black adults to 70.7% clear cell and 4.5% papillary in Latino adults. In multivariable analysis, non-Latino Black individuals had a higher likelihood of presenting with papillary (OR, 3.99; 95% confidence interval, 3.61–4.42) and chromophobe (OR, 1.81; 1.54–2.13) versus clear-cell subtype compared with non-Latino White individuals. Both hypertension (OR, 1.19; 1.10–1.29) and kidney disease (OR, 2.38; 2.04–2.77 end-stage disease; OR, 1.52; 1.33–1.72 non–end-stage disease) were associated with papillary subtype. Diabetes was inversely associated with both papillary (OR, 0.63; 0.58–0.69) and chromophobe (OR, 0.61; 0.54–0.70) subtypes.Conclusions:RCC subtype is independently associated with patient demographics, and comorbidity.Impact:Targeted RCC treatments or RCC prevention efforts may have differential impact across population subgroups.

  • Open Access

    Supplementary Table 3 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population

    by Daphne Y. Lichtensztajn, Brenda M. Hofer, John T. Leppert, James D. Brooks, Benjamin I. Chung, Sumit A. Shah, Mindy C. DeRouen, Iona Cheng

    Supplementary Table 3 shows the agreement between coded histology in registry data and electronic pathology reports

  • Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake

    by Nita H. Mukand, Ekaterina Chirikova, Daphne Lichtensztajn, Serban Negoita, Tamer Aboushwareb, John Bennett, James D. Brooks, John T. Leppert, Benjamin I. Chung, Christopher Li, et al.

    Background: The Oncotype DX Genomic Prostate Score (ODX‐GPS) is a gene expression assay that predicts disease aggressiveness. The objective of this study was to identify sociodemographic and regional factors associated with ODX‐GPS uptake.Methods: Data from Surveillance Epidemiology and End Results registries on men with localized prostate cancer with a Gleason score of 3 + 3 or 3 + 4, PSA ≤20 ng/mL, and stage T1c to T2c disease from 2013 through 2017 were linked with ODX‐GPS data. Census‐tract level neighborhood socioeconomic status (nSES) quintiles were constructed using a composite socioeconomic score. Multivariable logistic regression was used to estimate the associations of ODX‐GPS uptake with age at diagnosis, race and ethnicity, nSES, geographic region, insurance type, and marital status, accounting for National Comprehensive Cancer Network risk group, year of diagnosis, and clustering by census tract.Results: Among 111,434 eligible men, 5.5% had ODX‐GPS test uptake. Of these, 78.3% were non‐Hispanic White, 9.6% were Black, 6.7% were Hispanic, and 3.6% were Asian American. Black men had the lowest odds of ODX‐GPS uptake (odds ratio, 0.70; 95% confidence interval [CI], 0.63–0.76). Those in the highest versus lowest quintile of nSES were 1.64 times more likely (95% CI, 1.38–2.94) to have ODX‐GPS uptake. The odds of ODX‐GPS uptake were statistically significantly higher among men residing in the Northeast, West, and Midwest compared to the South.Conclusions: Disparities in ODX‐GPS uptake by race, ethnicity, nSES, and geographical region were identified. Concerted efforts should be made to ensure that this clinical test is equitably available.


  • Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population

    by Daphne Y. Lichtensztajn, Brenda M. Hofer, John T. Leppert, James D. Brooks, Benjamin I. Chung, Sumit A. Shah, Mindy C. DeRouen, Iona Cheng

    Background: Renal cell carcinoma (RCC) subtypes differ in molecular characteristics and prognosis. We investigated the associations of RCC subtype with patient demographics, comorbidity, and neighborhood socioeconomic status (nSES). Methods: Using linked California Cancer Registry and Office of Statewide Health Planning and Development data, we identified history of hypertension, diabetes, and kidney disease prior to RCC diagnosis in Asian/Pacific Islander, non-Latino Black, Latino, and non-Latino White adults diagnosed with their first pathologically confirmed RCC from 2005 through 2015. We used multinomial multivariable logistic regression to model the association of demographics, comorbidity, and nSES with clear-cell, papillary, and chromophobe RCC subtype. Results: Of the 40,016 RCC cases included, 62.6% were clear cell, 10.9% papillary, and 5.9% chromophobe. The distribution of subtypes differed strikingly by race and ethnicity, ranging from 40.4% clear cell and 30.4% papillary in non-Latino Black adults to 70.7% clear cell and 4.5% papillary in Latino adults. In multivariable analysis, non-Latino Black individuals had a higher likelihood of presenting with papillary (OR, 3.99; 95% confidence interval, 3.61–4.42) and chromophobe (OR, 1.81; 1.54–2.13) versus clear-cell subtype compared with non-Latino White individuals. Both hypertension (OR, 1.19; 1.10–1.29) and kidney disease (OR, 2.38; 2.04–2.77 end-stage disease; OR, 1.52; 1.33–1.72 non–end-stage disease) were associated with papillary subtype. Diabetes was inversely associated with both papillary (OR, 0.63; 0.58–0.69) and chromophobe (OR, 0.61; 0.54–0.70) subtypes. Conclusions: RCC subtype is independently associated with patient demographics, and comorbidity. Impact: Targeted RCC treatments or RCC prevention efforts may have differential impact across population subgroups.


  • Open Access

    Factors that influence treatment decisions: A qualitative study of racially and ethnically diverse patients with low‐ and very‐low risk prostate cancer

    by Alice Guan, Janet K. Shim, Laura Allen, Mei‐Chin Kuo, Kathie Lau, Zinnia Loya, James D. Brooks, Peter R. Carroll, Iona Cheng, Benjamin I. Chung, et al.

    Background: Factors that influence prostate cancer treatment decisions are complex, multifaceted, and personal, and may vary by race/ethnicity. Although research has been published to quantify factors involved in decision‐making, these studies have been limited to primarily white, and to a lesser extent, Black patients, and quantitative studies are limited for discerning the cultural and contextual processes that shape decision‐making.Methods: We conducted 43 semi‐structured interviews with a racially and ethnically diverse sample of patients diagnosed with low‐ and very‐low risk prostate cancer who had undergone treatment for their prostate cancer. Interviews were transcribed, independently coded, and analyzed to identify themes salient for decision‐making, with attention to sociocultural differences.Results: We found racial and ethnic differences in three areas. First, we found differences in how socialized masculinity influenced patient's feelings about different treatment options. Second, we found that for some men, religion and spirituality alleviated anxiety associated with the active surveillance protocol. Finally, for racially and ethnically minoritized patients, we found descriptions of how historic and social experiences within the healthcare system influenced decision‐making.Conclusions: Our study adds to the current literature by expounding on racial and ethnic differences in the multidimensional, nuanced factors related to decision‐making. Our findings suggest that factors associated with prostate cancer decision‐making can manifest differently across racial and ethnic groups, and provide some guidance for future research.